Royalty Pharma plc
For the period ended Mar 31, 2026. Filed May 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. OTHER INFORMATION
Rule 10b5-1 Trading Arrangements
The following table describes the written plans for the sale of our Class A ordinary shares adopted or terminated by our executive officers and directors during the first quarter of 2026, each of which is intended to satisfy the affirmative defense conditions of Rule 10b5-1 (each, a “Trading Plan”):
| Name and Title | Action | Adoption/ TerminationDate | Scheduled Expiration Date of Trading Plan(1) | Maximum Shares Subject to Trading Plan |
|---|---|---|---|---|
| Terrance Coyne Executive Vice President & Chief Financial Officer | Adoption | February 24, 2026 | August 17, 2026 | 214,091 and EPA Shares(2) |
| Christopher HiteExecutive Vice President & Chairman, Partnering & Investments | Adoption | March 20, 2026 | December 10, 2026 | 630,000 |
| Gregory NordenDirector | Adoption | February 12, 2026 | December 31, 2026 | 7,614 |
| Marshall Urist, M.D., Ph.D.Executive Vice President, Research & Investments | Adoption | February 12, 2026(3) | May 26, 2026(3) | 27,368 and EPA Shares(3) |
(1)A Trading Plan may expire on an earlier date if all contemplated transactions are completed before such Trading Plan’s expiration date, upon termination by broker or the holder of the Trading Plan, or as otherwise provided in the Trading Plan.
(2)Maximum shares subject to trading plan consists of up to 214,091 Class A ordinary shares and 100% of the shares that may be issued upon settlement of the EPAs awarded for the first and second quarters of 2026.
(3)On February 12, 2026, Dr. Urist entered into a Trading Plan, scheduled to commence on May 14, 2026 and end on May 26, 2026, providing for the sale of up to 27,368 Class A ordinary shares. In addition, on March 25, 2026, Dr. Urist entered into a Trading Plan, scheduled to commence on June 24, 2026 and end on July 9, 2026, providing for the sale of up to 50% of the shares that may be issued upon settlement of EPAs awarded for the first quarter of 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.